Alzheimer’s Society comment on development of drugs for dementia
Published 19 September 2012
Reports in today’s press (19 September 2012) speculate that major pharmaceutical companies are scaling down research and development of new drugs to treat dementia.
'Now is not the time to back away from dementia research. Despite costing the economy more than cancer and heart disease, funding for research into dementia is only a fraction of those conditions.
Currently there are 150 times more clinical trials focusing on treating people in the late stages of cancer than Alzheimer's disease.One in three people over the age of 65 will die with dementia. More funding for research is urgently needed if we are to defeat the condition once and for all.'
Director of External Affairs
News RSS feed
Visit Talking Point and take part in the discussions